未经批准:Drotaverine,痉挛症,已经发现有可能实现减少劳动持续时间并防止长期劳动。
UNASSIGNED:比较静脉注射盐酸多他维林与安慰剂对缩短初产妇活跃期分娩持续时间的影响。
未经批准:双盲,我们对246名处于足月活跃期的初产妇进行了安慰剂对照随机试验.他们被随机(1:1比例)静脉注射2ml(40mg)盐酸drotaverine或2ml维生素B复合物作为安慰剂。主要结果指标是活跃期的持续时间。次要结果指标是宫颈扩张率,催产素增加率,长时间分娩的发生率,分娩疼痛评分,交货方式,孕产妇和新生儿结局。
UNASSIGNED:与对照组相比,drotaverine组的活跃期平均持续时间(小时)显着降低(drotaverine;6.22±2.41vs安慰剂;8.33±3.56;p<0.001)。此外,drotaverine臂的宫颈扩张速率(cm/hr)显着更快(drotaverine;安慰剂为1.68±1.02;1.06±0.53,p<0.001)。在接受drotaverine的女性中,分娩速度更快的可能性明显更高(log-rank检验,p<0.001)。催产素增加率,长时间分娩的发生率,分娩疼痛评分,交货方式,各组间母婴结局无显著差异.
UNASSIGNED:盐酸Drotaverine可有效缩短活跃期的分娩时间,且无不良母婴结局。然而,需要更多的证据来探索其在初产妇积极分娩阶段的作用。试用注册号:PACTR201810902005232。
UNASSIGNED: Drotaverine, a spasmolytic, has been found to have potential to achieve a reduction in the duration of labour and prevent prolonged labour.
UNASSIGNED: To compare the effects of intravenous
drotaverine hydrochloride with placebo for shortening the duration of active phase of labour in primigravidas.
UNASSIGNED: A double-blind, placebo-controlled randomized trial of 246 primigravidas in active phase of labour at term was conducted. They were randomly (1:1 ratio) administered intravenous 2 ml (40mg) of
drotaverine hydrochloride or 2 ml of Vitamin B complex as placebo. The primary outcome measure was the duration of active phase of labour. The secondary outcome measures were cervical dilatation rate, oxytocin augmentation rate, incidence of prolonged labour, labour pain scores, mode of delivery, maternal and neonatal outcomes.
UNASSIGNED: The mean duration of active phase of labour (hour) was significantly lower in the drotaverine group compared to the control (
drotaverine; 6.22 ± 2.41 vs placebo; 8.33 ± 3.56; p <0.001). Also, the cervical dilatation rate (cm/hr) was significantly faster in the
drotaverine arm (
drotaverine; 1.68 ± 1.02 versus placebo; 1.06 ± 0.53, p <0.001). There was a significantly higher probability of faster delivery among women who were given drotaverine (log-rank test, p < 0.001). The oxytocin augmentation rate, incidence of prolonged labour, labour pain scores, mode of delivery, maternal and neonatal outcomes were not significantly different among the groups.
UNASSIGNED: Drotaverine hydrochloride is effective in shortening the duration of active phase of labour without adverse maternal and neonatal outcomes. However, more evidence is needed to explore its role in active phase of labour among primigravid women. Trial registration number: PACTR201810902005232.